Drug intelligence / Profile preview

HL-161

Development stage: Unknown
Lead developer: Shanghai KeChow Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

HL-161 is a small molecule, brain-penetrant BRAF inhibitor developed by KeChow Pharma. It is designed to selectively inhibit the BRAF V600 mutation, a key driver in the MAPK signaling pathway associated with various malignancies. Unlike many first-generation BRAF inhibitors, HL-161 is engineered for high blood-brain barrier permeability, addressing a significant unmet need in treating BRAF-mutant brain metastases and primary brain tumors such as gliomas. It is currently being evaluated in clinical trials for patients with advanced solid tumors harboring BRAF V600 mutations.

Targets

BRAF (B-Raf proto-oncogene, serine/threonine kinase)

Beyond the preview

Go deeper on HL-161.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HL-161.

Explore the full profile